Keywords: cellegy, prostrakan, cellegesic, deal, usa-based, pharmaceuticals, uk-headquartered
Cellegy and ProStrakan in Cellegesic deal
Article | 20 December 2004
USA-based Cellegy Pharmaceuticals and UK-headquartered ProStrakan have entered into an exclusive license agreement for the commercialization of Cellegesic (nitroglycerin ointment; ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
